[go: up one dir, main page]

WO2005097208A3 - Tissue oxygenation measurements - Google Patents

Tissue oxygenation measurements Download PDF

Info

Publication number
WO2005097208A3
WO2005097208A3 PCT/US2005/010112 US2005010112W WO2005097208A3 WO 2005097208 A3 WO2005097208 A3 WO 2005097208A3 US 2005010112 W US2005010112 W US 2005010112W WO 2005097208 A3 WO2005097208 A3 WO 2005097208A3
Authority
WO
WIPO (PCT)
Prior art keywords
tissue oxygenation
contrast agent
mri
methods
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/010112
Other languages
French (fr)
Other versions
WO2005097208A2 (en
Inventor
Edward Allan Ross
Christopher David Batich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
University of Florida Research Foundation Inc
Original Assignee
University of Florida
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida, University of Florida Research Foundation Inc filed Critical University of Florida
Publication of WO2005097208A2 publication Critical patent/WO2005097208A2/en
Publication of WO2005097208A3 publication Critical patent/WO2005097208A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicinal Preparation (AREA)

Abstract

An effective contrast agent for use in MRI-based methods for directly determining tissue oxygenation in a subject using MRI equipment as well as methods for assessing tissue oxygenation were discovered. Methods employ a blood substitute bound to a water soluble polymer as an MRI contrast agent. In the experiments described herein, polyethylene glycol (PEG) derivatives of bovine hemoglobin (pegylated Hb or PEG-Hb) were used as the contrast agent.
PCT/US2005/010112 2004-03-26 2005-03-25 Tissue oxygenation measurements Ceased WO2005097208A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55693204P 2004-03-26 2004-03-26
US60/556,932 2004-03-26

Publications (2)

Publication Number Publication Date
WO2005097208A2 WO2005097208A2 (en) 2005-10-20
WO2005097208A3 true WO2005097208A3 (en) 2006-01-26

Family

ID=35125629

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/010112 Ceased WO2005097208A2 (en) 2004-03-26 2005-03-25 Tissue oxygenation measurements

Country Status (1)

Country Link
WO (1) WO2005097208A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5377965B2 (en) 2005-09-09 2013-12-25 ジョージア ステート ユニバーシティ リサーチ ファウンデーション、インコーポレイテッド Targeted contrast agents and methods for targeting contrast agents
EP3498307A1 (en) 2008-04-02 2019-06-19 Georgia State University Research Foundation, Inc. Contrast agents, methods for preparing contrast agents, and methods of imaging
GB0812191D0 (en) * 2008-07-03 2008-08-13 Greater Glasgow Health Board Modified cells and methods of monitoring their viability
WO2010008594A1 (en) * 2008-07-18 2010-01-21 Oxygen Biotherapeutics, Inc. Method of treating traumatic brain injury
US10751464B2 (en) 2009-08-25 2020-08-25 Nanoshell Company, Llc Therapeutic retrieval of targets in biological fluids
US10099227B2 (en) 2009-08-25 2018-10-16 Nanoshell Company, Llc Method and apparatus for continuous removal of sub-micron sized particles in a closed loop liquid flow system
US11285494B2 (en) 2009-08-25 2022-03-29 Nanoshell Company, Llc Method and apparatus for continuous removal of sub-micron sized particles in a closed loop liquid flow system
WO2011025755A1 (en) 2009-08-25 2011-03-03 Agnes Ostafin Synthesis of oxygen carrying, turbulence resistant, high density submicron particulates
WO2011140193A1 (en) * 2010-05-04 2011-11-10 Massachusetts Institute Of Technology Implantable dissolved oxygen sensor and methods of use
WO2012044963A2 (en) 2010-10-01 2012-04-05 Oxygen Biotherapeutics, Inc. Perfluorocarbons for use in treating pruritus
CN105854034B (en) * 2016-06-23 2018-08-24 吉林大学 The poly- amino-pyrroles composite nanoparticle diagnosis and treatment reagent of metal ion Copper-cladding Aluminum Bar, preparation method and applications

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498421A (en) * 1993-02-22 1996-03-12 Vivorx Pharmaceuticals, Inc. Composition useful for in vivo delivery of biologics and methods employing same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498421A (en) * 1993-02-22 1996-03-12 Vivorx Pharmaceuticals, Inc. Composition useful for in vivo delivery of biologics and methods employing same

Also Published As

Publication number Publication date
WO2005097208A2 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
WO2005097208A3 (en) Tissue oxygenation measurements
Laven et al. Renal tolerance to prolonged warm ischemia time in a laparoscopic versus open surgery porcine model
EP1743591A3 (en) Apparatus for surgical navigation
WO2006054903A3 (en) Method of cardiac imaging with the use of hyperpolarized 13 c-pyruvate
WO2008053360A3 (en) Albumin binding molecules and uses thereof
ZA200701280B (en) MR imaging method for the discrimination between healthy and tumour tissue
EP1523951A3 (en) Method and apparatus for surgical navigation
WO2002054946A3 (en) Ultrasonic imaging of perfusion using gases with different partial pressures
WO2008078190A3 (en) Compounds for fluorescence imaging
WO2005079391A3 (en) Contrast agents for myocardial perfusion imaging
EP2332590A3 (en) Non-degradable low swelling, water soluble radiopaque hydrogels
CY1108689T1 (en) Oligopeptides for Reducing Increased Urine Concentration in Blood
BRPI0814339A2 (en) pharmaceutical composition, kit for the preparation of the pharmaceutical composition, conjugate and methods for in vivo optical imaging of the mammalian body, and for the detection, stabilization, diagnosis, monitoring of disease progress or monitoring of the treatment of a disease state. mammal body
WO2007106142A3 (en) Process for using optical agents
WO2012154218A3 (en) Reducing soluble urokinase receptor in the circulation
WO2005105159A3 (en) Contrast agents for myocardial perfusion imaging
WO2006090389A3 (en) Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
ATE383854T1 (en) COMBINATION OF SELECTED OPIOIDS WITH MUSCARINE ANTAGONISTS FOR THE THERAPY OF URINARY INCONTINENCE
TW200720648A (en) Oxidation-resistant indicator macromolecule
WO2009091556A3 (en) Diagnostic methods and kits using fibroblast growth factor-23
WO2007001339A3 (en) Ambient stored blood plasma expanders
WO2008055225A3 (en) Systems and methods for in vivo measurement of interstitial biological activity, processes and/or compositions
Shalabi et al. Impact of pneumoperitoneum on the post-operative renal function and level of acute kidney injury markers: comparison between laparoscopic and open nephrectomy
WO2008011573A3 (en) Pre- and intra- operative imaging of testicular torsion
WO2003001877A3 (en) Methods for the diagnosis and treatment of cardiac tissue rejection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase